
Stem, Inc. (STEM)
$
15.6
Key metrics
Financial statements
Free cash flow per share
-2.3621
Market cap
130.9 Million
Price to sales ratio
0.7935
Debt to equity
-1.3647
Current ratio
0.8256
Income quality
-0.1566
Average inventory
4.9 Million
ROE
-0.3243
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stem, Inc. operates as a digitally connected and intelligent energy storage network provider in the United States and internationally. The EBITDA is -$790,401,000.00 a key indicator of the company's operational profitability. The cost of revenue for the company is $155,642,000.00 showcasing its production and operational expenses. Despite its advanced solutions, the company reported a net loss of -$854,014,000.00 indicating challenges in its operations. Furthermore, the earnings per share (EPS) is reported at -$105.80 indicating the company's profitability on a per-share basis. The income before tax ratio is -$5.90 reflecting the pre-tax margin. Stem, Inc. provides energy storage systems sourced from original equipment manufacturers (OEMs) and offers its innovative Athena artificial intelligence platform, which delivers battery hardware and software-enabled services for optimal operation of energy storage systems. Additional services include system design and engineering, supply chain management, energy storage value stream optimization, and program enrollment and incentive management services. The company caters to commercial and industrial enterprises, independent power producers, renewable project developers, as well as utilities and grid operators, and it was incorporated in 2009 with headquarters in San Francisco, California. The stock is affordable at $18.10 suitable for budget-conscious investors. It also boasts a high average trading volume of 226,498.00 indicating strong liquidity. With a market capitalization of $130,887,245.00 the company is classified as a small-cap player. Stem, Inc. is a key player in the Software - Infrastructure industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Technology sector, driving innovation and growth. Overall, Stem, Inc. combines cutting-edge technology with proactive management to enhance energy storage solutions while navigating the complexities of the market effectively.
Investing in Stem, Inc. (STEM) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Stem, Inc. stock to fluctuate between $5.82 (low) and $32.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-02-02, Stem, Inc.'s market cap is $130,887,245, based on 8,390,208 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Stem, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Stem, Inc. (STEM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STEM. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Stem, Inc.'s last stock split was 1:20 on 2025-06-23.
Revenue: $144,584,000 | EPS: -$105.80 | Growth: 486.16%.
Visit https://www.stem.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $32.23 (2025-10-15) | All-time low: $0.29 (2025-04-16).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

accessnewswire.com
Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications PRINCETON, NJ, DAVIE, FL, AND TEL AVIV, ISRAEL / ACCESS Newswire / January 7, 2026 / Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and market access of biologics, today announced a comprehensive strategic partnership to advance and commercialize Cytora's novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the United States.

prnewswire.com
Three-Way Collaboration t o Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications PRINCETON, N.J. and DAVIE, Fla.

businesswire.com
HOUSTON--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM), a global leader reimagining technology to support the energy transition, today announced that its Board of Directors has increased the size of the Board from seven to eight directors, and appointed Arun Narayanan, Stem's Chief Executive Officer, to serve as a Class I Director, effective Dec. 1, 2025. The appointment reflects the Board's confidence in Narayanan's leadership and strategic vision as Stem continues to execute its transformation to.

defenseworld.net
Stem, Inc. (NYSE: STEM - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 1-year price target

seekingalpha.com
Stem, Inc. ( STEM ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Erin Reed Arun Narayanan - Chief Executive Officer Brian Musfeldt - Chief Financial Officer Conference Call Participants Justin Clare - ROTH Capital Partners, LLC, Research Division Jonathan Windham - UBS Investment Bank, Research Division Thomas Roche - Barclays Bank PLC, Research Division Presentation Operator Ladies and gentlemen, greetings, and welcome to the Stem, Inc. Third Quarter 2025 Results Conference Call. [Operator Instructions].

zacks.com
Stem, Inc. (STEM) came out with a quarterly loss of $2.84 per share versus the Zacks Consensus Estimate of a loss of $1.85. This compares to a loss of $4.2 per share a year ago.

247wallst.com
Stem beat on revenue but missed on earnings, causing the stock to sell off in after hours.

globenewswire.com
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will participate in a stem cell therapy panel titled, “A Space That is Ready to Have its Day,” at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City.

businesswire.com
BERLIN--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM), a global leader reimagining technology to support the energy transition, today announced the expansion of its Berlin operations with a move to centralized and collaborative facilities. The new office underscores Stem's commitment to advancing utility-scale solar, storage and hybrid solar-plus-storage projects across the EMEA region. The enhanced 400-square-meter space nearly doubles workspace capacity, bringing Stem's engineering, sales, and cus.
businesswire.com
HOUSTON--(BUSINESS WIRE)--Stem (NYSE: STEM), a global leader in AI-enabled clean energy software and services, will hold a conference call on Wed., Oct. 29, 2025, to discuss its results for the quarter ended Sept. 30, 2025. The conference call is scheduled to begin at 5:00 p.m. Eastern Time. A press release regarding the results will be issued at approximately 4:05 p.m. Eastern Time. The conference call may be accessed via a live webcast on a listen-only basis at https://investors.stem.com/even.
See all news